{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T08:38:05Z","timestamp":1743151085779,"version":"3.40.3"},"publisher-location":"Cham","reference-count":29,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783031545122"},{"type":"electronic","value":"9783031545139"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-54513-9_12","type":"book-chapter","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T18:06:38Z","timestamp":1715277998000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral Prescription Management"],"prefix":"10.1007","author":[{"given":"Aman","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parmvir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"issue":"6","key":"12_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4187\/respcare.06314","volume":"63","author":"DM Williams","year":"2018","unstructured":"Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63(6):655\u201370. https:\/\/doi.org\/10.4187\/respcare.06314. PMID: 29794202.","journal-title":"Respir Care"},{"key":"12_CR2","unstructured":"Corticosteroid (oral route, parenteral route) proper use. Mayo Clinic. September 1, 2023. Accessed 28 Sept 2023. https:\/\/www.mayoclinic.org\/drugs-supplements\/corticosteroid-oral-route-parenteral-route\/proper-use\/drg-20070491#:~:text=For%20oral%20dosage%20form%20(tablets,be%20determined%20by%20your%20doctor."},{"issue":"4","key":"12_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","volume":"78","author":"SH Yu","year":"2018","unstructured":"Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733\u2013740.e11. https:\/\/doi.org\/10.1016\/j.jaad.2017.09.074. Epub 2017 Dec 6. PMID: 29032119.","journal-title":"J Am Acad Dermatol"},{"key":"12_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s003930070032","volume":"59 Suppl 1","author":"E Schacht","year":"2000","unstructured":"Schacht E. Osteoporose bei rheumatoider Arthritis--Bedeutung von Alfacalcidol in Pr\u00e4vention und Therapie [Osteoporosis in rheumatoid arthritis--significance of alfacalcidol in prevention and therapy]. Z Rheumatol. 2000;59 Suppl 1:10\u201320. German. https:\/\/doi.org\/10.1007\/s003930070032. PMID: 10769429.","journal-title":"Z Rheumatol"},{"key":"12_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","volume":"71(2)","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Simpson EL, Tom WL, Williams HC, Elmets CA, Block J, Harrod CG, Begolka WS, Eichenfield LF. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.030. Epub 2014 May 9. PMID: 24813298; PMCID: PMC4410179.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"12_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaad.2009.05.048","volume":"62","author":"M Rosenbach","year":"2010","unstructured":"Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr. Van Voorhees AS; National Psoriasis Foundation Medical Board. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655\u201362. https:\/\/doi.org\/10.1016\/j.jaad.2009.05.048. Epub 2009 Aug 8. PMID: 19665821.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"12_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1365-2133.2009.09561.x","volume":"162","author":"J Schmitt","year":"2010","unstructured":"Schmitt J, Sch\u00e4kel K, F\u00f6lster-Holst R, Bauer A, Oertel R, Augustin M, Aberer W, Luger T, Meurer M. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol. 2010;162(3):661\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09561.x. Epub 2009 Oct 26. PMID: 19863501.","journal-title":"Br J Dermatol"},{"issue":"2","key":"12_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","volume":"133","author":"E Roekevisch","year":"2014","unstructured":"Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429\u201338. https:\/\/doi.org\/10.1016\/j.jaci.2013.07.049. Epub 2013 Oct 24. PMID: 24269258.","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/480642","volume":"2011","author":"AK Singh","year":"2011","unstructured":"Singh AK, Narsipur SS. Cyclosporine: a commentary on brand versus generic formulation exchange. J Transp Secur. 2011;2011:480642. https:\/\/doi.org\/10.1155\/2011\/480642.","journal-title":"J Transp Secur"},{"issue":"5","key":"12_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40264-013-0034-x","volume":"36","author":"K Paziana","year":"2013","unstructured":"Paziana K, Del Monaco M, Cardonick E, Moritz M, Keller M, Smith B, Coscia L, Armenti V. Ciclosporin use during pregnancy. Drug Saf. 2013;36(5):279\u201394. https:\/\/doi.org\/10.1007\/s40264-013-0034-x. PMID: 23516008.","journal-title":"Drug Saf"},{"issue":"4","key":"12_CR11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1001\/archdermatol.2011.79","volume":"147","author":"ME Schram","year":"2011","unstructured":"Schram ME, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ. Spuls PI; Off-Label Working and Project Group of Dutch Society of Dermatology and Venereology. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol. 2011;147(4):474\u201388. https:\/\/doi.org\/10.1001\/archdermatol.2011.79. PMID: 21482898.","journal-title":"Arch Dermatol"},{"issue":"2","key":"12_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1046\/j.1365-2133.2002.04989.x","volume":"147","author":"J Berth-Jones","year":"2002","unstructured":"Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, Hotchkiss K, Graham-Brown RA. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147(2):324\u201330. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04989.x. PMID: 12174106.","journal-title":"Br J Dermatol"},{"issue":"2","key":"12_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1046\/j.1365-2133.2002.04922.x","volume":"147","author":"LA Murphy","year":"2002","unstructured":"Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol. 2002;147(2):308\u201315. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04922.x. PMID: 12174104.","journal-title":"Br J Dermatol"},{"issue":"4","key":"12_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1440-1746.2010.06254.x","volume":"25","author":"RB Gearry","year":"2010","unstructured":"Gearry RB, Day AS, Barclay ML, Leong RW, Sparrow MP. Azathioprine and allopurinol: a two-edged interaction. J Gastroenterol Hepatol. 2010;25(4):653\u20135. https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06254.x. PMID: 20492321.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"12_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1365-2133.2000.03667.x","volume":"143","author":"K Neuber","year":"2000","unstructured":"Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol. 2000;143(2):385\u201391. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03667.x. PMID: 10951150.","journal-title":"Br J Dermatol"},{"issue":"1","key":"12_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/09546634.2018.1468068","volume":"30","author":"D Dias-Polak","year":"2019","unstructured":"Dias-Polak D, Bergman R, Avitan-Hersh E. Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis. J Dermatolog Treat. 2019;30(1):49\u201351. https:\/\/doi.org\/10.1080\/09546634.2018.1468068. Epub 2018 May 10. PMID: 29683760.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"12_CR17","first-page":"870","volume":"137","author":"M Grundmann-Kollmann","year":"2001","unstructured":"Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke WH, Kaufmann R, Zollner TM. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol. 2001;137(7):870\u20133. PMID: 11453805.","journal-title":"Arch Dermatol"},{"key":"12_CR18","volume-title":"StatPearls [Internet]","author":"JC Leek","year":"2023","unstructured":"Leek JC, Arif H. Pregnancy medications. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507858\/."},{"key":"12_CR19","unstructured":"Drugs and Lactation Database (LactMed\u00ae) [Internet]. Bethesda: National Institute of Child Health and Human Development; 2006-. Mycophenolate. [Updated 2023 Jul 15]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501638\/"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148(4)","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.009. Epub 2021 Aug 24. PMID: 34437922; PMCID: PMC10166130.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"12_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.anai.2023.01.020","volume":"130","author":"D Mikhaylov","year":"2023","unstructured":"Mikhaylov D, Ungar B, Renert-Yuval Y, Guttman-Yassky E. Oral Janus kinase inhibitors for atopic dermatitis. Ann Allergy Asthma Immunol. 2023;130(5):577\u201392. https:\/\/doi.org\/10.1016\/j.anai.2023.01.020. Epub 2023 Feb 1. PMID: 36736457.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"12_CR22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E. Efficacy and safety of Oral Janus Kinase 1 inhibitor Abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2855. Erratum in: JAMA Dermatol. 2020 Jan 1;156(1):104. PMID: 31577341; PMCID: PMC6777226.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"12_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, Magnolo N, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(20)30732-7. PMID: 32711801.","journal-title":"Lancet"},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397(10290)","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Tha\u00e7i D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2. Epub 2021 May 21. Erratum in: Lancet. 2021 Jun 5;397(10290):2150. PMID: 34023008.","journal-title":"Lancet"},{"issue":"3","key":"12_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, Hong HC, Papp KA, Reich K, Beck LA, Mohamed MF, Othman AA, Anderson JK, Gu Y, Teixeira HD, Silverberg JI. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.025. Epub 2019 Nov 29. PMID: 31786154.","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jdcr.2023.01.020","volume":"33","author":"N Shahriari","year":"2023","unstructured":"Shahriari N, Strober B, Shahriari M. JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: a case series of 6 patients. JAAD Case Rep. 2023;33:81\u20133. https:\/\/doi.org\/10.1016\/j.jdcr.2023.01.020. PMID: 36873051; PMCID: PMC9982443.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"12_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13(3):729\u201349. https:\/\/doi.org\/10.1007\/s13555-023-00892-5. Epub 2023 Feb 15. PMID: 36790724; PMCID: PMC9930707","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"12_CR28","doi-asserted-by":"publisher","first-page":"e1735","DOI":"10.1542\/peds.2014-2812","volume":"134","author":"MM Tollefson","year":"2014","unstructured":"Tollefson MM, Bruckner AL. Section on dermatology. Atopic dermatitis: skin-directed management. Pediatrics. 2014;134(6):e1735\u201344. https:\/\/doi.org\/10.1542\/peds.2014-2812. PMID: 25422009.","journal-title":"Pediatrics"},{"key":"12_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-4419-8056-4_8","volume":"709","author":"J Buddenkotte","year":"2010","unstructured":"Buddenkotte J, Maurer M, Steinhoff M. Histamine and antihistamines in atopic dermatitis. Adv Exp Med Biol. 2010;709:73\u201380. https:\/\/doi.org\/10.1007\/978-1-4419-8056-4_8. PMID: 21618889.","journal-title":"Adv Exp Med Biol"}],"container-title":["Advances in Experimental Medicine and Biology","Management of Atopic Dermatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-54513-9_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T18:09:53Z","timestamp":1715278193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-54513-9_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031545122","9783031545139"],"references-count":29,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-54513-9_12","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"10 May 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}